A prospective study suggests that incident cardiovascular disease (CVD) event risk depends on the time course of cumulative prior exposure to low-density lipoprotein cholesterol (LDL-C), the younger the age of exposure accumulation, the greater risk increase. The study included 4,958 asymptomatic adults age 18 to 30 years enrolled from 1985 […]
Two studies suggest that reproductive life span and adverse pregnancy outcomes are sex-specific risk factors for atherosclerotic cardiovascular disease (CVD) in women. One study included 307 855 women from 12 studies. Overall, the mean ages at menarche, menopause, and reproductive life span were 13.0, 50.2, and 37.2 years, respectively. Pooled analyses […]
The American Heart Association just issued a scientific statement for drug-induced arrhythmias. Drugs from many therapeutic classes may cause or ex-acerbate a variety of arrhythmias. Awareness of drugs that may cause arrhythmias and specific arrhythmias that may be drug induced is important. Numerus drugs can prolong the QT interval and […]
A systematic review suggested that Intensive blood pressure (BP)-lowering treatment decreases risk for orthostatic hypotension (OH). OH, before or in the setting of more intensive BP treatment, should not be viewed as a reason to avoid or de-escalate treatment for hypertension. The data were extracted from 5 trials examined BP […]
A meta-analyses and Mendelian randomization study identified causal risk factors for type 2 diabetes (T2D). The study found evidence of causal associations between 34 exposures (19 risk factors and 15 protective factors) and T2D. Insomnia was identified as a novel risk factor (OR 1.17). The other 18 risk factors were […]
An international, investigator-initiated, parallel-group, open, blinded-outcome-assessment trial concluded that early rhythm-control therapy was associated with a lower risk of cardiovascular (CV) outcomes than usual care among patients with early atrial fibrillation (AF) and CV conditions. A total of 2789 patients who had early AF (diagnosed ≤1 year before enrollment, median […]
A randomized, controlled, double-blind trial showed that 0.5 mg of colchicine once daily significantly reduced cardiovascular disease (CVD) events in patients with chronic coronary disease in Australia and the Netherlands. The trial included 5522 patients, >80% male, 35 to 82 years of age (2762 assigned to colchicine and 2760 to […]